Global Intravenous Iron Drugs Market - Size, Projections, Drivers, Trends, Vendors, and Analysis Through 2021 by Technavio

Technavio has published a new report on the global intravenous iron drugs market from 2017-2021. (Graphic: Business Wire)

LONDON--()--According to the latest market study released by Technavio, the global intravenous iron drugs market is projected to grow to USD 2,206.11 million by 2021, at a CAGR of more than 10% over the forecast period.

This research report titled ‘Global Intravenous Iron Drugs Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

Intravenous (IV) iron drugs are administered via intravenous access to quickly restore iron in the blood stream using a small tube. The growing demand for non-dextran intravenous iron drugs due to their ability to deliver larger doses of iron in shorter durations is a key driver of the market.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Based on the product type, the report categorizes the global intravenous iron drugs market into the following segments:

  • Ferric carboxymaltose
  • Sucrose
  • Dextran
  • Others

The top three revenue-generating product segments in the global intravenous iron drugs market are discussed below:

Ferric carboxymaltose

The ferric carboxymaltose segment occupied a majority 42% of the global market in 2016. The segment’s dominance is expected to continue, driven by their safety, efficacy profile, and ability to rapidly replenish iron stores in the body,” says Sapna Jha, a lead analyst at Technavio for cardiovascular and metabolic disorders research.

Ferric carboxymaltose is a new parenteral dextran-free drug used to treat iron deficiency and the first of the new drugs approved for rapid and high-dose replacement of depleted iron stores. It can be safely administered in higher doses compared to other conventional drugs, which makes it extremely useful in emergency situations.


The intravenous iron drugs market by sucrose is expected to be worth USD 502.15 million by 2021. Sucrose is mainly used for the treatment of iron deficiency anemia in individuals with chronic kidney disease. It is one of the oldest IV iron drugs and replenishes body iron stores effectively. Galenica and Sanofi are some of the key players that offer intravenous sucrose iron solutions. The increasing popularity of sucrose to treat anemia in emerging economies will benefit the growth of the market segment through the forecast period.


High molecular weight dextran is one of the very first approved intravenous iron drugs used for the treatment of iron deficiency. The popular dextran drugs include Allergan’s INFeD, Pharmacosmos’ CosmoFer, and Daiichi Sankyo’s DEXIron,” says Sapna.

Low-molecular-weight dextran products are the least expensive intravenous iron drugs and can be administered in a single, large dose. This market segment has reached saturation, and its growth is expected to stabilize through the forecast period owing to the advent of alternative novel drugs with better safety and efficacy profiles.

The top vendors highlighted by Technavio’s research analysts in this report are:

  • Allergan
  • AMAG Pharmaceuticals
  • Galenica
  • Pharmacosmos

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, in-vitro diagnostics, and oncology. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770

Release Summary

According to the latest market study released by Technavio, the global intravenous iron drugs market is projected to grow to USD 2,206.11 million by 2021, at a CAGR of more than 10%.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770